Toyota Motor Corporation (TMC) has decided to establish an in-house venture company responsible for developing electric vehicles.

The venture company, which will be a virtual organization consisting of four persons―one each from Toyota Industries Corporation, Aisin Seiki Co., Ltd., Denso Corporation and TMC―and which will be independent of other internal structural organizations, is set to launch in December 2016.

In the development of EVs, the venture company will draw on the technological knowhow and resources of the Toyota Group. Its small organizational structure is meant to enable it to implement unconventional work processes, leading to accelerated project progress and, thus, fast-to-market products.

Based on its thinking to provide the right vehicle at the right place at the right time, TMC has long taken a multi-angled approach to introducing environment-friendly vehicles andenzyme HMG CoA reductase, which catalyzes production of mevalonic acid from HMG CoA and represents the therapeutic target for statins. Cholesterol produced by liver is either secreted in bile or incorporated into lipoproteins (mainly VLDL) and secreted into plasma.

Intestinal cholesterol absorption represents another major route for the entry of cholesterol into the body, and, thus, this source can influence LDL-C concentration ([@b56]). Daily the cholesterol pool in the intestine comes from either dietary cholesterol (300--500 mg), from biliary excretion (800--1200 mg) and from desquamated cells (300 mg) ([@b34]; [@b56]). Of note, as a large part of the cholesterol absorbed results from the reabsorbtion of cholesterol excreted through the bile, it is appropriate to talk about entero-hepatic recirculation). The excess cholesterol is then excreted through the feces. Although the